Chris Ryan

Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.

(PUEBLO, Colo.) — Reigning state-runner up Palmer Ridge (1-0) exploded to an early 21-0 lead and never looked back in an opening night 35-14 victory over Pueblo East (0-1) on Thursday night at Dutch Clark Stadium. The Bears play La Cueva in their home opener on Friday, August 28. The Eagles will eye their first […]

Key Takeaways Cereblon-binding CELMoDs intensify IKZF1/3 degradation beyond classic IMiDs, potentially combining direct tumor cytotoxicity with immune effector activation and reduced T-cell exhaustion. At 100 µg daily plus dexamethasone, ORR reached 53% (CBR 63%) with sCR/CR in 16% and responses maintained across post–CAR T or TCE exposure. Median PFS was 3.9 months across dose levels and median DOR 7.9 months; MRD negativity occurred in two responders at the RP2D. Hematologic toxicity was dominated by neutropenia (grade 3/4: 22%/36%), usually managed with dose modification and G-CSF; discontinuations and reductions were uncommon (4% and 7%). MOMENTUM is an open-label, multicenter, single-arm phase 2 trial using 100 µg on 14-days-on/14-days-off plus weekly dexamethasone in heavily exposed refractory disease. SHOW MORE

Key Takeaways Targeting the hepcidin axis addresses persistent real-world failure to maintain hematocrit <45% and mitigates phlebotomy-associated iron deficiency, fatigue, and cognitive symptoms in polycythemia vera. IMPRSSION met its primary end point in both dose cohorts, markedly lowering weekly phlebotomy rates and median phlebotomy counts, alongside dose- and time-dependent hepcidin increases. Safety in IMPRSSION was generally manageable; anemia predominated, injection-site reactions were mild, and one AML transformation death was deemed unrelated to treatment. INTREPID enrolls ~250 patients in a double-blind 32-week comparison of sapablursen 80 mg Q4W vs placebo, with crossover and a 104-week safety extension. Integration could include monotherapy for lower-risk patients otherwise managed with phlebotomy alone or add-on therapy to cytoreduction when hematocrit control remains inadequate. SHOW MORE

Peter Voorhees, MD, discusses the integration of CAR T-cell therapy in early-relapsed myeloma and the importance of early T-cell–redirecting therapy use.

Advertisement The FDA has approved rusfertide (Mimrylo) for the treatment of adult patients with polycythemia vera.

Fact checked by: Riley Kandel Advertisement The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adult patients with essential thrombocythemia (ET).

JAK Inhibitor Selection in Myelofibrosis Ruxolitinib remains a go-to first choice for proliferative myelofibrosis, where platelet counts are adequate and anemia is not significant.

Key Takeaways Hepcidin modulation addresses persistent real-world failure to maintain hematocrit <45% and mitigates phlebotomy-driven iron deficiency, fatigue, and cognitive symptoms in polycythemia vera. IMPRSSION met its primary end point, reducing phlebotomy rates and median phlebotomies (baseline 5.0 to 0.0–1.5), alongside sustained hematocrit reductions and increased hepcidin. Symptom burden improved, particularly at higher dosing, as reflected by MPN-SAF-TSS changes, reinforcing a class effect seen with hepcidin-pathway agents beyond hematocrit control. INTREPID enrolls ~250 phlebotomy-dependent patients regardless of background cytoreduction, using a 32-week blinded period with primary end point of phlebotomy ineligibility from weeks 20–32. Monthly sapablursen could function as monotherapy in lower-risk disease or adjunct to cytoreductives when hematocrit remains inadequately controlled, offering a pragmatic dosing interval versus competitors. SHOW MORE